Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin’s Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg – Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).
Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School – Dana-Farber Cancer Institute.
Covering four important studies:
– TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations
– CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma
– CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma
– THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration
Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with Dr. Virginia Kaklamani – Professor of Medicine – Leader of Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center.
Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead author, Dr. Aditya Bardia – Associate Professor at Massachusetts General Hospital – Harvard Medical School.
OncBrothers Copyright 2023 © All Right Reserved.
Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology
